A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

INR Patient Self-Testing


Stephan Moll, MD writes…

INR testing in patients on warfarin is classically done in a physician’s office or anticoagulation clinic, via (a) i.v. blood draw and central lab testing, or (b) a finger-stick and testing on a POC (point-of-care) device. POC devices give reliable INR results.

INR Home Testing is Reliable, Safe and Effective

INR point-of-care devices are also available to patients for INR self-testing. They are often reimbursable by insurance carriers.  And warfarin management through patient self-testing at home is at least as effective and safe as INR testing through a medical practice. The well-done large 2011 THINRS trial clearly showed this, and a Nov 2011 systematic review of the medical literature confirms that [ref 1,2].

If I were a Patient on Warfarin…

If I were a patient on long-term warfarin, I would want an INR home testing device.  It would give me independence; wouldn’t have to waste my time with clinic visits just to have my INRs checked; have breakfast – stick finger, get INR– go to work or play. That’s what I’d want, short of preferring to be on a well-established, reversible oral anticoagulant that does not require routine anticoagulation monitoring.

Why Is INR Self Testing Not More Popular in the U.S.?

All published data convince me that INR home testing is effective and safe and the right thing to do – in appropriately selected and well-trained patients. Of course, some patients are not suitable for self-testing. But the THINRS trial showed that a many patients (80 %) are suitable and trainable. So, why do many physicians and anticoagulation clinics not offer it to their patients?

  1. Reimbursement reasons: Yes, the testing devices and test strips are often paid for by insurers, but INR home testing is unattractive for many health care practice settings because of the often un-billable phone management services or the loss of income from not having patients come to billable clinic visits. Yes, one can bill for the phone management service, but the reimbursement (ca. $10.00 per month) is often not worth the effort needed to collect that money. There is, regrettable, not much financial incentive to offer INR home testing to patients.
  2. Hassle: Getting a patient a device, getting the patient’s INR results phoned into the clinic, and managing warfarin over the distance is involved with some hassle, paperwork, a need for a good clerical structure to make this a safe management option. Many health care providers seem to perceive the hassle of this not worth the effort.
  3. Control: A number of health care providers are hesitant to give up control and may feel vulnerable to litigation if a bad outcome (bleed or thrombosis) happens to their patient who does INR home monitoring. The present systematic review should aid in dispersing that concern, as it shows that outcomes in appropriately trained patients are not worse than in individuals who receive anticoagulation monitoring care by coming to a clinic for INR testing. I have actually heard the provocative comment that physicians who do NOT offer their patients INR home testing are liable if a bad outcome occurs, as the present systematic review showed that INR home monitoring is associated less thrombotic events and should, thus, be the preferred management strategy. I wouldn’t go so far to support that statement, but it reflects that one could certainly present INR home testing in suitable patients as THE gold-standard of care.
  4. Lack of awareness and knowledge:  There may also be a component of unawareness – amongst health care professionals, and clearly amongst patients on warfarin – that INR home testing is available, reliable, safe and effective. Hopefully, the THINRs trial and the present systematic review help increase awareness of this viable monitoring option; and disperse the unwarranted concerns that INR home testing devices are not reliable or the majority of patients not suitable for it.

Conclusion

I conclude as I started: If I were a patient on long-term warfarin, I would want an INR home monitor. I am afraid, though, my physician or anticoagulation pharmacist would say: ‘Can’t do it; our practice is not set up to do it; too much hassle, too much paperwork, no worthwhile reimbursement’. I bet if I were to beg enough, they would eventually provide me with the INR home monitoring option – but only as a favor to me as a medical colleague and as an exception to their practice. I wish, however, that every suitable patient could have the option of having warfarin managed via INR home monitoring. It is safe and effective and the right thing to do for good patient service. My advice to patients interested in INR self-testing: tell the pharmacist and MD who manages your anticoagulation that you are interested in INR self testing and ask them whether they would support it.

References

  1. Matchar B et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med, 2010; 363: 1608-1620.
  2. Heneghan C et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. Available online 30 November 2011.

 

Disclosure:  I have received research support (material support, not financial) from International Technidyne Corporation.

Last updated: Jan 24th, 2012


Leave a comment. Please understand we cannot give individual medical advice.